Kelun-Biotech Will Present Updates for A166 at ASCO

Kelun-Biotech will attend the 2021 ASCO Annual Meeting from June 4-8. We will report the results from a Phase 1 study of A166 in Chinese patients with locally advanced or metastatic solid tumors (CTR20181301).

Link to Abstract: https://meetinglibrary.asco.org/record/195765/abstract
Link to Poster: https://00b59142-f99b-461b-a0e8-499f02d7f596.usrfiles.com/ugd/00b591_4c17bf4fb60d478aac82049b308961e7.pdf

A166 is an antibody-drug conjugate composed of a novel cytotoxic drug (Duo-5, anti-microtubule agent) site-specifically conjugated to an anti-HER2 antibody (trastuzumab) via a stable protease-cleavable valine citrulline linker. The study included 57 patients with a majority having high HER2 expressing solid tumors. No DLTs were observed in all dose groups. The ORR in the 4.8 and 6.0 mg/kg cohorts were 59.1% (13/22) and 71.4% (10/14), respectively. Median progression-free survival (PFS) was not reached, and one patient in the 4.8 mg/kg cohort has been on treatment for more than 19 months. A166 demonstrated promising antitumor activity with clinically meaningful responses in heavily pretreated subjects with HER2-positive breast cancer. These results support the further development of A166 in clinical trials for the treatment of HER2+ solid tumors.

A166 is currently available for partnerships worldwide. Inquiries are welcome and may be directed to bd@kluspharma.com